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Detection of minimal residual disease identifies differences in treatment response
between T-ALL and precursor B-ALL
Marja J. Willemse, Taku Seriu, Klaudia Hettinger, Elisabetta d’Aniello, Wim C. J. Hop, E. Renate Panzer-Gru¨mayer, Andrea Biondi,
Martin Schrappe, Willem A. Kamps, Guiseppe Masera, Helmut Gadner, Hansjoerg Riehm, Claus R. Bartram, and Jacques J. M. van Dongen
We performed sensitive polymerase chain
reaction–based minimal residual disease
(MRD) analyses on bone marrow samples
at 9 follow-up time points in 71 children
with T-lineage acute lymphoblastic leuke-
mia (T-ALL) and compared the results
with the precursor B-lineage ALL (B-ALL)
results (n  210) of our previous study. At
the first 5 follow-up time points, the fre-
quency of MRD-positive patients and the
MRD levels were higher in T-ALL than in
precursor-B-ALL, reflecting the more fre-
quent occurrence of resistant disease in
T-ALL. Subsequently, patients were clas-
sified according to their MRD level at time
point 1 (TP1), taken at the end of induc-
tion treatment (5 weeks), and at TP2 just
before the start of consolidation treat-
ment (3 months). Patients were consid-
ered at low risk if TP1 and TP2 were MRD
negative and at high risk if MRD levels at
TP1 and TP2 were 103 or higher; remain-
ing patients were considered at intermedi-
ate risk. The relative distribution of pa-
tients with T-ALL (n  43) over the MRD-
based risk groups differed significantly
from that of precursor B-ALL (n  109).
Twenty-three percent of patients with T-
ALL and 46% of patients with precursor
B-ALL were classified in the low-risk
group (P  .01) and had a 5-year relapse-
free survival (RFS) rate of 98% or greater.
In contrast, 28% of patients with T-ALL
were classified in the MRD-based high-
risk group compared to only 11% of pa-
tients with precursor B-ALL (P  .02), and
the RFS rates were 0% and 25%, respec-
tively (P  .03). Not only was the distribu-
tion of patients with T-ALL different over
the MRD-based risk groups, the prognos-
tic value of MRD levels at TP1 and TP2
was higher in T-ALL (larger RFS gradi-
ent), and consistently higher RFS rates
were found for MRD-negative T-ALL pa-
tients at the first 5 follow-up time points.
(Blood. 2002;99:4386-4393)
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Introduction
Childhood acute lymphoblastic leukemia (ALL) has a B-lineage
origin in approximately 85% of patients and a T-lineage origin in
the remaining approximately 15% of patients.1 Typical T-lineage
ALL (T-ALL) is diagnosed in male adolescents and is frequently
characterized by hyperleukocytosis, mediastinal mass, and central
nervous system involvement.2,3 Children with T-ALL generally
have a poorer prognosis than those with precursor B-lineage ALL
(B-ALL).1,4 In T-ALL, the following characteristics were shown
to have a negative effect on treatment outcome: patient age 15
years or older, L2 blast morphology, karyotype other than
hyperdiploidy, and CD3.2,3 The most immature T-ALLs (CD1/
CD3) are also associated with unfavorable outcome, whereas
CD1 T-ALL forms a distinct subgroup with an excellent
prognosis on intensive high-risk treatment.4-7 Early in vivo
response has been identified as one of the strongest prognostic
factors in childhood ALL.8-12 Patients with T-ALL frequently
have a poor in vivo steroid response9,12,13 and are resistant to
many drugs, as demonstrated by in vitro assays.14 Nevertheless,
treatment outcome has significantly improved, and the sustained
relapse-free survival (RFS) rate is 60% to 70% in patients with
T-ALL on intensive chemotherapy.15-17
Individualization of ALL treatment might further improve
outcome and long-term quality of life. This may be achieved
through minimal residual disease (MRD) studies that allow the
sensitive detection of leukemic cells undetectable by normal
cytomorphologic examination, thereby providing accurate informa-
tion about the in vivo efficacy of cytotoxic treatment.18,19 The most
broadly applicable MRD technique in ALL is polymerase chain
reaction (PCR) analysis of clone-specific immunoglobulin and
T-cell receptor (TCR) gene rearrangements, which are easily
identified in most pediatric and adult patients with ALL.19-21 Based
on the sequences of the patient-specific junctional regions, sensitivi-
ties of 104 to 105 (one leukemic cell in 10 000 to 100 000 normal
cells) are reached.22
Several large-scale studies in childhood ALL have shown that
MRD analysis can predict outcome by determining the reduction of
the leukemic cell burden during the first months of therapy.23-27
Multivariate analysis showed that MRD information is an important
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prognostic factor at all follow-up time points taken during and after
treatment and that this MRD information is independent of the
classical clinical parameters at diagnosis such as age, sex, white
blood cell count (WBC), immunophenotype, chromosome aberra-
tions, and prednisone response.25-27 For example, prognostically
relevant subgroups such as T-ALL or ALL characterized by t(9;22),
t(12,21), or t(4;11) are still heterogeneous in treatment re-
sponse,2,28-31 but MRD information during treatment of these
leukemia subtypes is more discriminative in predicting treatment
outcome.26,32,33
The impact of MRD information in childhood ALL appeared to
be superior to classical treatment group classification at diagnosis,
as was demonstrated by the study of the International BFM Study
Group (I-BFM-SG). In this study, a precise risk group classification
was achieved by combining sensitive (104 or less) MRD informa-
tion of 2 follow-up time points (TP): TP1, at the end of induction
treatment, and TP2, just before the start of consolidation treat-
ment.27 Three risk groups were identified: a low-risk group
consisting of 43% of the patients with MRD negativity at TP1 and
TP2 and a 5-year RFS of 98%; a high-risk group of 15% of patients
with high MRD levels (103 or more) at both time points and a
5-year RFS of 16%; and an intermediate-risk group consisting of
the 43% remaining patients with a 5-year RFS of 76% (updated
RFS data). In this risk-group classification, TP1 appeared to be
particularly useful for recognizing low-risk patients and TP2 for the
recognition of high-risk patients, whereas later time points (particu-
larly TP5) provided prognostic value for further classification of
intermediate-risk patients.27 The above-described MRD-based risk
group classification is used for treatment stratification in child-
hood ALL protocols of the BFM–Associazione Italiana di Ematolo-
gia ed Oncologia Pediatrica (AIEOP) (M.S., G.M., H.G., unpub-
lished results, July 2000).
The aim of the present MRD study was to identify the different
response groups within T-ALL and to elucidate the differences in
overall treatment response between T-ALL and precursor B-ALL.
From the cohort of patients included in the I-BFM-SG study, we
were able to analyze 71 patients with T-ALL for their MRD pattern
using one or 2 TCR gene rearrangements as PCR targets. These
data were used to compare the presenting features and outcomes of
the 71 patients with T-ALL with those of the previously reported
210 precursor B-ALL cases.27
Patients, materials, and methods
Patients and cell samples
Bone marrow (BM) samples at diagnosis and as many as 9 time points
during follow-up were collected from patients with childhood T-ALL
included in the I-BFM-SG MRD study. Follow-up time points were: TP1, at
the end of induction treatment (5 weeks); TP2, before consolidation (3
months); TP3, before reinduction treatment (6 months); TP4, before
maintenance treatment (9 months); TP5, at 12 months; TP6, at 15 months;
TP7, at 18 months; TP8, at the end of treatment (24 months); and TP9, at 1
year off treatment (36 months) (Figure 1A).27 Mononuclear cells (MNCs)
were isolated from the collected BM samples and were stored in liquid
nitrogen or at70°C for DNA extraction.
All children were treated according to protocols of the Austrian BFM
Group (protocol ALL-BFM 90), the German BFM Group (protocol
ALL-BFM 90), the AIEOP-ALL-91 protocol, or the Dutch Childhood
Leukemia Study Group (DCLSG, protocol ALL-8).12,34,35 The 3 treatment
protocols all had the same I-BFM-SG backbone. Patients with T-ALL were
stratified into 2 treatment groups, medium-risk group (MRG) and high-risk
group (HRG), according to the presenting features such as leukemic cell
mass and prednisone response.12,34,35 All patient samples were obtained
according to the informed consent guidelines of the local or national
medical ethics committees.
The cohort of childhood ALL included in the I-BFM-SG MRD study
from March 1991 to May 1995 (n 625) contained 74 patients with T-ALL
(12%); 30 had been previously analyzed.27 In the present study, 41 of the 44
remaining patients with T-ALL could be analyzed according to the same
criteria—morphologic remission was reached at the end of induction
treatment (at TP1), no BM samples were missing from more than 3
consecutive follow-up time points or from more than 4 follow-up time
points in total, and at least one PCR target with a sensitivity of at least 104
was available for MRD detection. Of the total 71 patients with T-ALL,
24 had been treated in Germany, 20 in The Netherlands, 15 in Italy, and
12 in Austria.
The earlier analyzed group of precursor B-ALL was sufficiently large
(n  210) for the comparative T-ALL versus precursor B-ALL study and
did not require the inclusion of extra patients. Five-year RFS rates of the
analyzed T-ALL group (n 71) were 60% (6% SE) compared with 76%
(3%) in the precursor B-ALL group (Figure 1B). Survival of the T-ALL
group studied is comparable to that of the total group of patients with
T-ALL treated according to the same protocol.12,34,35 Patient characteristics
of the 71 T-ALL and the 210 precursor B-ALL patients are given in Table 1.
Figure 1. I-BFM-SG treatment protocol and RFS of T-ALL and precursor B-ALL. (A) Hypothetical graph shows the kinetics of leukemic cell decrease and regrowth in
several ALL patients during and after treatment with the I-BFM-SG treatment protocol. MRD curves represent individual patients of the 3 MRD-based risk groups27—2 patients
with slow MRD clearance and in the high-risk group; 2 patients with moderate MRD clearance and in the intermediate-risk group; and one patient with rapid MRD clearance in
the low-risk group. The detection limit of cytomorphologic techniques and the detection-limit range of the PCR technique are indicated. Vertical arrows represent BM sampling
time points at diagnosis, before each treatment block, at several time points during maintenance treatment, at cessation of therapy, and 1 year thereafter. I indicates induction
treatment; C, consolidation treatment; II, reinduction treatment. (B) RFS of the 71 T-ALL and the 210 precursor B-ALL patients. Tick marks indicate censored survival times.
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Identification of PCR targets at diagnosis
The junctional regions of TCR gamma (TCRG) and TCR delta (TCRD)
gene rearrangements were used as patient-specific targets for PCR-based
MRD detection.22,36,37 In addition, the so-called TAL1 deletions were used
as PCR targets in some patients with T-ALL.22,38 Primers and PCR
protocols were as described in the report of the BIOMED-1 Concerted
Action BMH-CMT 94-1675.22 Clonal rearrangements in the TCRG, TCRD,
and TAL1 genes were identified by heteroduplex PCR analysis and direct
sequencing of the junctional regions with standardized sets of oligonucleo-
tide primers.22,39 Based on the sequence data of the junctional regions,
patient-specific oligonucleotides were designed for each identified MRD-
PCR target as described previously, using OLIGO software (W. Rychlik;
Molecular Biology Insights, Cascade, CO).22
PCR-based MRD detection during follow-up
The MRD-PCR analyses of BM samples during follow-up of the patients
with T-ALL were performed as described in the earlier BIOMED-1 report.22
Briefly, single PCR amplification with the standardized primer sets of the
clone-specific rearrangement using 1 g DNA (equivalent to 105-106 cells)
was followed by dot blotting and hybridization with the corresponding
32P-labeled, patient-specific junctional region probe. Radioactive signals
were evaluated using phosphor imaging. The sensitivity of each identified
MRD-PCR target was established by use of a dilution experiment, in which
DNA from the leukemic cells at diagnosis was diluted in 10-fold dilution
steps into control DNA from a mixture of blood MNCs of 10 different
healthy donors. Preferably, 2 independent PCR targets were used per
patient, of which at least one reached a sensitivity of at least 104.
When MRD-PCR analysis of BM follow-up samples resulted in a
hybridization signal, this time point was considered to be MRD positive.
Consequently, if no signal was obtained, this time point was considered
MRD negative, irrespective of the PCR target sensitivity. The frequency of
leukemic cells in the BM samples during follow-up was estimated by
comparison of the signals with those of the 10-fold dilution samples of
DNA at diagnosis. This resulted in reproducible semiquantitative estima-
tions of MRD-PCR results of 102, 103, 104, 105, and 106 or more. If
analysis of the same BM sample with 2 independent PCR targets resulted in
different MRD level estimations, we assumed the highest MRD level to be
the most accurate for data analysis, because lower MRD levels might be
caused by subclone formation through continuing rearrangement pro-
cesses.19,27 The following MRD levels were defined: high MRD levels of
102 or more, intermediate MRD levels of 103, and low MRD levels of
104 or less. MRD-PCR results of 105 and 106 were clustered with the
104 results because such low MRD levels were rarely found.
Statistical analyses
Relative frequencies were compared between groups using the 2 of Fisher
exact test. Between- and within-group comparisons of MRD levels were
made using the Mann-Whitney U and the Wilcoxon test, respectively. RFS
according to the MRD results at the various time points was determined
using Kaplan-Meier plots. Comparison of groups was performed using the
log rank test or the log rank trend test for ordered groups (eg, MRD levels).
Multivariate analysis of the predictive value of MRD at the various time
points, allowing for different other variables (treatment group, age, sex,
WBC on a continuous scale, and prednisone response) was performed using
Cox regression analysis. It was further analyzed whether the prognostic
effects of MRD levels differed between T-ALL and precursor B-ALL by
investigating appropriate interaction terms in the regression models.
P  .05 was considered significant.
Results
Number of MRD-PCR targets
In 66% (47 of 71) of the patients with T-ALL, 2 PCR targets (42
patients) or 3 PCR targets (5 patients) were used for MRD
detection. The remaining 34% of patients with T-ALL were
analyzed by one MRD-PCR target. The 123 PCR targets used in the
patients with T-ALL comprised 89 TCRG gene rearrangements, 10
incomplete TCRD gene rearrangements, 20 complete TCRD gene
rearrangements, and 4 TAL1 deletions. In 76% (93 of 123) of these
targets, sensitivities of at least 104 were reached: 58 targets had a
sensitivity of 104, 28 targets had 105, and 7 targets had 106.
In the precursor B-ALL group, 40% (84 of 210) of patients were
monitored with one MRD-PCR target and 60% (126 of 210) were
monitored with 2 targets (113 patients) or 3 targets (13 patients).
Use of 1, 2, or 3 MRD-PCR targets did not significantly differ
between T-ALL and precursor B-ALL (P  .4).
MRD in T-ALL is distinct from precursor B-ALL
At the time of morphologic remission (TP1), that is, at 5 weeks of
treatment, 80% (43 of 54) of patients with T-ALL were still MRD
positive in contrast to 54% (78 of 144) patients with precursor
Figure 2. Frequencies. Frequency of MRD-positive patients at each individual
follow-up time point for T-ALL and precursor B-ALL.







SRG (%) 0 62 (30)
MRG (%) 50 (70) 135 (64)
HRG (%) 21 (30) 13 (6)
Sex
Male (%) 56 (79) 109 (52)
Female (%) 15 (21) 101 (48)
Age distribution in months
Mean (range) 104 (0-200) 64 (10-204)
WBC count at diagnosis
Median 109/L (range) 87 (3-700) 12 (1-550)
Prednisone response
Good (%) 54 (76) 200 (95)
Poor (%) 17 (24) 10 (5)
Five-year RFS rates (%)* (no. relapses)
SRG – 84 (10)
MRG 75 (12) 78 (30)
HRG 24 (16) 23 (10)
All patients 60 (28) 76 (50)
Significant differences were found between T-ALL and precursor B-ALL for all
parameters (P .001).
*Median relapse-free follow-up time of CCR patients is 63 months for T-ALL and
72 months for precursor B-ALL.
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B-ALL. In both groups the frequency of positive patients at TP2
(just before consolidation treatment) had approximately halved
compared with the frequency found at TP1: 45% (25 of 55) in the
T-ALL group and 26% (40 of 156) in the precursor B-ALL group.
A further decrease at later time points was similar in both groups,
but the frequency of MRD-positive patients remained higher in
patients with T-ALL compared with patients with precursor B-ALL
until halfway through maintenance treatment (mean difference,
14% 13%) (Figure 2).
Not only the frequency of MRD-positive patients but also the
level of MRD at the first 3 time points was significantly higher
in T-ALL than in precursor B-ALL (all P  .004). In both
groups, the MRD levels decreased from TP1 to TP2 (P  .001).
In precursor B-ALL, this reduction of MRD level was also
observed from TP2 to TP3 (P  .01). Such a decrease was not
clear in patients with T-ALL (P  .85), in whom most MRD
levels were equal at TP2 and TP3, or when evaluated per patient
(equal in 76% of patients).
MRD levels did not differ significantly between patients
analyzed with one MRD-PCR target and patients with 2 or 3
MRD-PCR targets. This applied to all time points in T-ALL and
precursor B-ALL.
Prognostic value of MRD in T-ALL is higher than in
precursor B-ALL
At each follow-up time point, MRD levels were highly associated
with subsequent relapse rates: the higher the MRD level, the worse
the prognosis (P[trend] .001). Patients with T-ALL (n 15)
who were MRD negative or who had low MRD levels (104 or
lower) at TP1 had a 5-year RFS rate of 100%. The 5-year RFS rates
of patients with MRD-negative precursor B-ALL at TP1 were 96%
(2%) and 74% (8%) for patients with low MRD levels (Figure
3). High MRD levels (102 or more) at TP1 resulted in a
significantly lower 5-year RFS rates in T-ALL patients than in
patients with precursor B-ALL—14% (8%) and 35% (11%),
respectively (P  .04). This difference in RFS between precursor
B-ALL and T-ALL was also found at TP2 for high MRD levels
(P  .01) and intermediate MRD levels (103) (P  .05). At TP3,
patients with MRD-negative T-ALL had a 5-year RFS rate of 97%
(3%) compared with 86% (3%) in precursor B-ALL (not
significant), and patients with MRD-positive T-ALL had a 5-year
RFS rate of 22% (8%) compared with 30% (8%) in precursor
B-ALL (not significant). From TP2 onward, the discrimination
between survival of MRD-positive and MRD-negative patients was
always better in patients with T-ALL than in patients with precursor
Figure 3. RFS according to MRD informa-
tion at the first 3 follow-up time points in
T-ALL and precursor B-ALL. (A) repre-
sents the MRD data obtained from T-ALL,
and (B) represents data from precursor
B-ALL. The number of patients is given for
each MRD level. Tick marks indicate cen-
sored survival times.
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B-ALL. Although apparent, these differences between T-ALL and
precursor B-ALL were not always significant.
The prognostic value of MRD level differed significantly
between T-ALL and precursor B-ALL at TP1 and TP2 (P  .03 and
P  .01, respectively). Using Cox regression analysis, it was found
that with each 10-fold decrease in MRD level at TP1 (from 102 or
more to 103 to 104 or less to negative), the relapse rate was
reduced by 84% in T-ALL compared with 62% in precursor
B-ALL. This difference in gradient of RFS between T-ALL and
precursor B-ALL was similar at TP2: for each drop in MRD level,
the relapse rate was reduced by 79% in T-ALL compared with 61%
in precursor B-ALL. At both time points, the observed differences
in gradient of RFS between T-ALL and precursor B-ALL were not
significantly affected by WBC count at diagnosis.
MRD-based risk group classification
The previously defined MRD-based risk group classification re-
quires MRD information of TP1 and TP2. Patients at low risk were
MRD negative at both time points, patients at high risk had MRD
levels of 103 or higher at both time points, and the remaining
patients formed the intermediate-risk group.27 Forty-three patients
with T-ALL and 109 patients with precursor B-ALL could be
analyzed at TP1 and TP2 and could consequently be classified.
These patient subgroups did not differ significantly from the groups
that lacked one or both time points with respect to distribution of
age, sex, treatment group, and survival.
More than twice as many patients with T-ALL were classified in
the MRD-based high-risk group than patients with precursor
B-ALL—28% (12 of 43) versus 11% (12 of 109), respectively
(P  .02). The size of the intermediate-risk group was comparable
for T-ALL (49%; 21 of 43) and precursor B-ALL (43%; 47 of 109)
patients. Consequently, fewer patients with T-ALL than patients
with precursor B-ALL were classified at low risk: 23% of T-ALL
(10 of 43) compared with 46% of precursor B-ALL (50 of 109)
(P  .01). In addition, the survival rates of the corresponding risk
groups were similar: 5-year RFS rates in the low-risk group were
100% for T-ALL and 98% for precursor B-ALL (P  .65). The
5-year RFS in the intermediate-risk group was 76% for T-ALL and
77% for precursor B-ALL (P  .78). A significant difference was
found between the 5-year RFS rates for patients with T-ALL and
patients with precursor B-ALL only in the high-risk group: 0% and
25%, respectively (P  .03) (Figure 4).
The distribution of 1 versus 2 or 3 MRD-PCR targets did not
significantly differ between the MRD-based risk groups of patients
with T-ALL (P .28) and patients with precursor B-ALL (P .27),
though the numbers of patients in some subgroups were low.
Further classification of MRD-based intermediate-risk patients
Later time points may have additional value for recognizing
patients at good and poor risk in the MRD-based intermediate-risk
group. MRD information of the BM sample taken just before
reinduction treatment (TP3) did not have a significant additional
value for patients with intermediate-risk precursor B-ALL (P .08).
On the other hand, for patients with intermediate-risk T-ALL, at
TP3 a significant difference in outcome was found between
MRD-negative patients (n 10, 5-year RFS of 100%) and MRD-
positive patients (n 8, 5-year RFS of 38%) (P  .004). TP4 (start
of maintenance treatment) also seemed to be of additional value for
the intermediate-risk T-ALL group in contrast to precursor B-ALL;
MRD-negative patients with T-ALL (n 11) had a 5-year RFS of
82%, and MRD-positive patients (n 3) had a 5-year RFS of 0%
(P  .002). As found previously, TP5 at 1 year is an interesting
time point for further monitoring patients with ALL initially
classified as at intermediate risk. This holds true for precursor
B-ALL and for T-ALL. We found significant differences between
MRD-positive and MRD-negative patients, despite low patient
numbers (P  .001 for T-ALL and P  .004 for precursor B-ALL).
Because of the larger gradient of RFS according to MRD levels
at TP1 and TP2 in T-ALL and the consistently lower relapse rates in
the patients with MRD-negative T-ALL compared with patients
with precursor B-ALL (Figure 3), one would expect it to be easier
to discriminate between good and poor treatment responses in
patients with T-ALL in the MRD-based intermediate-risk group.
Indeed, the 10 T-ALL patients with seemingly moderate treatment
responses at TP1, as defined by low or intermediate MRD levels (
103) but MRD negativity at TP2, had excellent outcomes (0 of 10
relapses). The corresponding group of patients with precursor
B-ALL has a relatively high relapse rate (25%; 7 of 28).
Association between MRD-based risk group classification and
T-ALL maturational stage
Based on immunophenotype, patients with T-ALL could be catego-
rized as having immature CD1/CD3 T-ALL (n 17), CD1
T-ALL (n 37), and mature CD1/CD3 T-ALL (n 17) with
5-year RFS rates of 47%, 72%, and 41%, respectively. The 43
patients with T-ALL of the MRD-based risk group classification
comprised 12 immature T-ALL, 25 CD1 T-ALL, and 6 mature
Figure 4. RFS according to the MRD-based risk group classification as defined by MRD information at TP1 and TP2. Patients in the low-risk group are characterized by
MRD negativity at both time points, patients in the high-risk group are characterized by MRD levels 103 or greater at both time points, and the remaining patients form the
intermediate-risk group. (A) 43 T-ALL patients. (B) 109 precursor B-ALL patients. For each MRD-based risk group, the number of patients and the relative size of each risk
group are given. Tick marks indicate censored survival times.
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T-ALL. The 25 CD1 T-ALL patients were not randomly distrib-
uted over the MRD-based risk groups. In line with the relatively
good prognosis of CD1 T-ALL, they represented 90% (9 of 10) of
the MRD-based low-risk group and 57% (12 of 21) of the
MRD-based intermediate risk group but only 33% (4 of 12) of the
MRD-based high-risk group (P  .01). In addition, the 12 imma-
ture CD1/CD3 T-ALL were not randomly distributed over the
MRD-based risk groups: no immature patients with T-ALL were
classified as low risk, whereas 5 were classified as MRD-based
high risk and the remaining 7 were classified as intermediate risk.
Despite the low patient numbers, these findings were in line with
the difference in 5-year RFS between these 2 immunophenotypic
subgroups. For the small group of mature CD3 T-ALL patients
(n  6), no association with MRD-based risk groups was detected.
Prognostic value of MRD in the T-ALL patient group
Multivariate analysis was performed for the 71 patients with
T-ALL. Simultaneous evaluation of MRD-based risk group and
treatment group showed that both factors were significantly related
to RFS (P  .001 and P  .03, respectively). No additional
prognostic value was found for age, sex, prednisone response, and
WBC count on a continuous scale, although the latter weakly
correlated with the MRD-based risk group classification.
Discussion
T-lineage ALL is associated with more high-risk features than
precursor B-ALL.2,4 Despite the improvement in outcome by
intensive chemotherapy, patients with T-ALL generally have a
significantly worse RFS than patients with precursor B-ALL.1,4,12,34
This difference in outcome was reflected by the MRD pattern when
studying 9 follow-up time points taken during and after treatment
by sensitive PCR techniques (detection limit 104 or less). At most
time points the frequency of MRD-positive patients and the MRD
levels were higher in the T-ALL group than in the precursor B-ALL
group, reflecting the more frequent resistant disease in the
T-ALL group.
Recently, MRD was proven to be the most important prognostic
parameter in several large prospective studies.25-27 Now we confirm
that also within the relatively small subgroup of T-ALL patients,
MRD is a highly relevant prognostic factor. The impact of MRD
level information differed significantly between T-ALL and precur-
sor B-ALL at early time points, TP1 and TP2. For each 10-fold
decrease in MRD level, approximately 80% fewer relapses were
found in T-ALL compared with approximately 60% fewer relapses
in precursor B-ALL.
Our results are consistent with those of previous MRD studies
in T-ALL, which showed that MRD correlated with outcome.40,41
Dibenedetto et al41 found that the presence of MRD at the
beginning of maintenance treatment was the strongest predictor of
poor outcome. In our study MRD information at this relatively late
time point was predictive. However, our semiquantitative MRD
technique allowed us to discriminate between patients with good
and poor prognoses at earlier time points, which is essential for
early treatment stratification.
The currently applied MRD-based risk group classification in
childhood ALL, which is based on the kinetics of tumor reduction
during the first 3 months of treatment, was found to be valid for
T-ALL as well. All patients with T-ALL who were classified in the
MRD-based high-risk group subsequently relapsed. Half of the
patients with T-ALL were classified as at intermediate risk with a
5-year RFS rate of 76%, and 23% of the patients with T-ALL were
classified as at low risk with a 100% RFS rate. Survival in the
intermediate-risk and low-risk groups was similar to that in
precursor B-ALL; only survival in the high-risk group was
different in T-ALL than in precursor B-ALL (0% vs 25%). The
distribution of T-ALL over the MRD-based risk groups was distinct
from that of precursor B-ALL (Figure 4). More than twice as many
patients with T-ALL were classified in the high-risk group (28% vs
11%), but the T-ALL low-risk group was half the size of the
precursor B-ALL low-risk group (23% vs 46%). Consequently,
approximately half of the patients with T-ALL belonged in the
intermediate-risk group. MRD monitoring at later time points
(TP3, TP4, TP5) gave additional prognostic value for the patients
with intermediate-risk T-ALL who were classified as good and poor
risk based on the absence and presence of MRD at each time point,
respectively. Further monitoring of intermediate-risk precursor
B-ALL was less valuable (only TP5 gave a significant difference),
probably reflecting the larger heterogeneity in this ALL subgroup.
Several BFM studies have shown the power of the initial
prednisone response for recognition of many patients at high
risk.8,9,12,29,42,43 However, our previous MRD study demonstrated
that the prednisone response had no additional value on top of the
MRD-based risk group classification.27 In addition, in this study,
MRD information was a stronger prognostic factor than the
prednisone response. Only 3 of 12 MRD-based high-risk precursor
B-ALL patients and only 8 of 12 MRD-based high-risk T-ALL
patients were predicted by poor prednisone response; all 11 patients
had relapses. The other patients with poor prednisone response
(n  8) all belonged to the MRD-based intermediate-risk group,
and half of them (4 of 8) had relapses.
The distribution of patients with T-ALL over the MRD-based
high-risk and low-risk groups seemed straightforward, showing
either a resistant MRD pattern with 100% relapses or MRD
negativity at TP1 and TP2 with 0% relapses, respectively. How-
ever, 10 intermediate-risk T-ALL patients with moderate MRD
levels (103 or less) at TP1 and MRD negativity at TP2 also
appeared to have excellent prognoses with no relapses. These
observations are in contrast to patients with precursor B-ALL; 23%
of MRD-based high-risk precursor B-ALL patients are still in
continuous complete remission, and moderate MRD levels (103 or
lower) at TP1 followed by MRD negativity at TP2 was still
associated with 25% relapses in precursor B-ALL. This significant
difference in prognostic value of MRD information between
T-ALL and precursor B-ALL is in line with the larger gradient of
RFS according to MRD levels at TP1 and TP2 in T-ALL (Figure 3)
and the consistently lower relapse rates in the MRD-negative
T-ALL patients at the first 5 follow-up time points.
When the 10 intermediate-risk T-ALL patients with moderate
MRD levels at TP1 and MRD negativity at TP2 were shifted to
the MRD-based low-risk group, the MRD-based risk group
classification further improved—46% (20 of 43) low-risk pa-
tients with 0% relapses, 26% (11 of 43) intermediate-risk
patients with 45% relapses, and 28% (12 of 43) high-risk
patients with 100% relapses. This remarkable separation of the 3
risk groups must be confirmed in larger series of patients with
T-ALL. Nevertheless, we tried to understand the biologic
significance of this observation and hypothesized that the MRD
level at TP1 in patients with T-ALL might be influenced by the
WBC count at diagnosis, because a good treatment response
might not always result in MRD negativity at TP1 in patients
with high initial WBC counts. We indeed found that the 10
T-ALL patients with MRD negativity at TP1 and TP2 had a low
median WBC count of 25  109/L, whereas the 10 patients with
moderate MRD levels at TP1 (103 or less) but MRD negativity
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at TP2 had a higher median WBC count of 135  109/L. This
difference in WBC count was not statistically significant,
possibly because of the relatively small number of patients.
Our MRD study shows that the MRD-based risk-group classifi-
cation is highly valuable for T-ALL. Within 3 months of diagnosis,
MRD analysis allowed the recognition of therapy-resistant T-ALL
patients (28%) with poor outcomes and a substantial group of
T-ALL patients (23% or even 47%) with excellent prognoses. This
implies that up to 75% of patients with T-ALL might be classified
as either low-risk or high-risk patients. Although the overall
survival rate of T-ALL is lower than that of precursor B-ALL, still
60% to 70% of patients with T-ALL are long-term survivors.15-17
Many of these survivors can now probably be recognized as
low-risk T-ALL patients. These data further support the application
of MRD kinetic information for treatment stratification in child-
hood ALL. It should be emphasized that for this purpose the MRD
techniques should reach sensitivities of at least 104.
Independent from prognostic parameters at diagnosis, MRD analysis
provides direct insight into the in vivo drug sensitivity ofALL cells. Our
study shows that this type of information allows a highly accurate
prediction of outcome within the 2 major immunophenotypic ALL
categories, particularly in T-ALL. It can be anticipated that sensitive
MRD analysis comprises a tool to define distinct risk groups within
other seemingly homogeneous prognostic categories, such as leukemias
with a particular chromosomal aberration.
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